Skip to main content
editor@theusajournals.com | Oscar Publishing Services Journal Home
Login

American Journal Of Biomedical Science & Pharmaceutical Innovation

Peer Reviewed | Open Access | E-ISSN: 2771-2753
Published Article

Innovations in Managing Decompensated Cirrhosis: A Review of Contemporary Treatment Strategies

Innovations in Managing Decompensated Cirrhosis: A Review of Contemporary Treatment Strategies

Authors

  • Dr. Samuel Chen
    Department of Internal Medicine, Pacific Rim Medical Center, Vancouver, Canada

Keywords:

Liver Cirrhosis Decompensated Cirrhosis Portal Hypertension

Abstract

Background: Liver cirrhosis, the end-stage of chronic liver disease, is a major cause of global morbidity and mortality. Its clinical course is characterized by the development of life-threatening complications, including portal hypertension, ascites, hepatic encephalopathy (HE), hepatorenal syndrome-acute kidney injury (HRS-AKI), and hepatocellular carcinoma (HCC). The management of these conditions is complex and has evolved significantly in recent years.

Objective: This review aims to synthesize recent evidence and provide a comprehensive overview of the contemporary, evidence-based strategies for the diagnosis and management of the major complications of decompensated liver cirrhosis.

Methods: A narrative review of the literature was conducted using prominent databases. The synthesis focuses on seminal studies, clinical guidelines, and recent trials that have shaped the current understanding and treatment paradigms for cirrhosis complications, drawing from a curated list of 34 key references.

Findings: Management of portal hypertension and varices has been refined with non-invasive diagnostics and clear prophylactic strategies. For ascites, the focus remains on diuretic management and timely intervention for refractory cases, while new insights into bacterascites and spontaneous bacterial peritonitis (SBP) have improved infection control. The treatment of HE is centered on ammonia-lowering agents like lactulose and rifaximin. The diagnostic criteria for HRS-AKI have been updated for earlier recognition, with vasoconstrictors (e.g., terlipressin) and albumin forming the cornerstone of medical therapy. For HCC, enhanced risk stratification models and regular surveillance in cirrhotic patients are critical for early detection and access to potentially curative therapies.

Conclusion: The management of cirrhosis complications has advanced significantly, moving towards earlier diagnosis and targeted, evidence-based interventions. A multi-faceted approach addressing each complication is crucial for improving patient outcomes. Future research should focus on novel therapies targeting the underlying pathophysiology of portal hypertension and fibrosis to prevent decompensation and improve survival.

References

Schuppan D, Afdhal NH. Liver cirrhosis. Lancet. 2008;371(9615):838-851. doi:10.1016/S0140-6736(08)60383-9

Huang DQ, Terrault NA, Tacke F, et al. Global epidemiology of cirrhosis - aetiology, trends and predictions. Nat Rev Gastroenterol Hepatol. 2023;20(6):388-398. doi:10.1038/s41575-023-00759-2

GBD 2016 Brain and Other CNS Cancer Collaborators. Global, regional, and national burden of brain and other CNS cancer, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(4):376-393. doi:10.1016/S1474-4422(18)30468-X

Flemming JA, Djerboua M, Groome PA, Booth CM, Terrault NA. NAFLD and alcohol-associated liver disease will be responsible for almost all new diagnoses of cirrhosis in Canada by 2040. Hepatology. 2021;74(6):3330-3344. doi:10.1002/hep.32032

Nusrat S, Khan MS, Fazili J, Madhoun MF. Cirrhosis and its complications: evidence based treatment. World J Gastroenterol. 2014;20(18):5442-5460. doi:10.3748/wjg.v20.i18.5442

Smethurst K, Gallacher J, Jopson L, et al. Improved outcomes following the implementation of a decompensated cirrhosis discharge bundle. Frontline Gastroenterol. 2022;13(5):409-415. doi:10.1136/flgastro-2021-101900

Kalaitzakis E. Quality of life in liver cirrhosis. In: Preedy VR, Watson RR, eds. Handbook of Disease Burdens and Quality of Life Measures. Springer; 2010:2239-2254. doi:10.1007/978-0-387-78665-0_134

Iwakiri Y. Pathophysiology of portal hypertension. Clin Liver Dis. 2014;18(2):281-291. doi:10.1016/j.cld.2013.12.001

Oliver TI, Sharma B, John S. Portal Hypertension. In: StatPearls. StatPearls Publishing; 2023.

Shen M, Lee A, Lefkowitch JH, Worman HJ. Vibration-controlled transient elastography for assessment of liver fibrosis at a USA academic medical center. J Clin Transl Hepatol. 2022;10(2):197-206. doi:10.14218/JCTH.2021.00263

Meseeha M, Attia M. Esophageal Varices. In: StatPearls. StatPearls Publishing; 2023.

Shaheen AA, Nguyen HH, Congly SE, Kaplan GG, Swain MG. Nationwide estimates and risk factors of hospital readmission in patients with cirrhosis in the United States. Liver Int. 2019;39(5):878-884. doi:10.1111/liv.14054

Moore CM, Van Thiel DH. Cirrhotic ascites review: Pathophysiology, diagnosis and management. World J Hepatol. 2013;5(5):251-263. doi:10.4254/wjh.v5.i5.251

Runyon BA. Management of adult patients with ascites due to cirrhosis: an update. Hepatology. 2009;49(6):2087-2107. doi:10.1002/hep.22853

Shahed FHM, Mamun-Al-Mahtab N, Rahman S. The evaluation of serum ascites albumin gradient and portal hypertensive changes in cirrhotic patients with ascites. Euroasian J Hepatogastroenterol. 2016;6(1):8-9. doi:10.5005/jp-journals-10018-1158

Fiati Kenston SS, Song X, Li Z, Zhao J. Mechanistic insight, diagnosis, and treatment of ammonia-induced hepatic encephalopathy. J Gastroenterol Hepatol. 2019;34(1):31-39. doi:10.1111/jgh.14418

Levitt DG, Levitt MD. A model of blood-ammonia homeostasis based on a quantitative analysis of nitrogen metabolism in the multiple organs involved in the production, catabolism, and excretion of ammonia in humans. Clin Exp Gastroenterol. 2018;11:193-215. doi:10.2147/CEG.S160921

Maraolo AE, Gentile I, Pinchera B, Nappa S, Borgia G. Current and emerging pharmacotherapy for the treatment of bacterial peritonitis. Expert Opin Pharmacother. 2018;19(12):1317-1325. doi:10.1080/14656566.2018.1509952

MacIntosh T. Emergency management of spontaneous bacterial peritonitis - a clinical review. Cureus. 2018;10(3):e2253. doi:10.7759/cureus.2253

Oey RC, van Buuren HR, de Jong DM, Erler NS, de Man RA. Bacterascites: A study of clinical features, microbiological findings, and clinical significance. Liver Int. 2018;38(12):2199-2209. doi:10.1111/liv.13893

Ng CK, Chan MH, Tai MH, Lam CW. Hepatorenal syndrome. Clin Biochem Rev. 2007;28(1):11-17.

Orr TG, Helwig FC. Liver trauma and the hepatorenal syndrome. Ann Surg. 1939;110(4):682-692. doi:10.1097/00000658-193910000-00012

Arroyo V, Ginès P, Gerbes AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology. 1996;23(1):164-176. doi:10.1002/hep.510230122

Amin AA, Alabsawy EI, Jalan R, Davenport A. Epidemiology, pathophysiology, and management of hepatorenal syndrome. Semin Nephrol. 2019;39(1):17-30. doi:10.1016/j.semnephrol.2018.10.002

Adebayo D, Wong F. Pathophysiology of hepatorenal syndrome - acute kidney injury. Clin Gastroenterol Hepatol. 2023;21(3):S1-S10. doi:10.1016/j.cgh.2022.11.035

Egerod Israelsen M, Gluud LL, Krag A. Acute kidney injury and hepatorenal syndrome in cirrhosis. J Gastroenterol Hepatol. 2015;30(2):236-243. doi:10.1111/jgh.12709

Angeli P, Ginès P, Wong F, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: Revised consensus recommendations of the International Club of Ascites. J Hepatol. 2015;62(4):968-974. doi:10.1016/j.jhep.2014.12.029

Benvegnù L, Gios M, Boccato S, Alberti A. Natural history of compensated viral cirrhosis: A prospective study on the incidence and hierarchy of major complications. Gut. 2004;53(5):744-749. doi:10.1136/gut.2003.020263

Simonetti RG, Cammà C, Fiorello F, et al. Hepatocellular carcinoma. A worldwide problem and the major risk factors. Dig Dis Sci. 1991;36(7):962-972. doi:10.1007/BF01297149

Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: Incidence and risk factors. Gastroenterology. 2004;127(5 Suppl 1):S35-S50. doi:10.1053/j.gastro.2004.09.014

Reddy KR, McLerran D, Marsh T, et al. Incidence and risk factors for hepatocellular carcinoma in cirrhosis: The multicenter hepatocellular carcinoma early detection strategy (HEDS) study. Gastroenterology. 2023;165(1):1053-1063.e6. doi:10.1053/j.gastro.2023.06.012

Flemming JA, Yang JD, Vittinghoff E, Kim WR, Terrault NA. Risk prediction of hepatocellular carcinoma in patients with cirrhosis: The ADRESS-HCC risk model. Cancer. 2014;120(22):3485-3493. doi:10.1002/cncr.28832

De Mitri MS, Poussin K, Baccarini P, et al. HCV-associated liver cancer without cirrhosis. Lancet. 1995;345(8947):413-415. doi:10.1016/s0140-6736(95)90398-4

Ramakrishna G, Rastogi A, Trehanpati N, et al. From cirrhosis to hepatocellular carcinoma: New molecular insights on inflammation and cellular senescence. Liver Cancer. 2013;2(3-4):367-383. doi:10.1159/000343852.